Despite misgivings about the adequacy and controls of two open-label Phase III trials in evaluating Genzyme Corp.’s Lemtrada in relapsing-remitting multiple sclerosis (MS), the Peripheral and Central Nervous System Drugs Advisory Committee seemed to support approval of the drug, but not as a first-line therapy and only with a strong risk evaluation and mitigation strategy (REMS).